Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc. (“Co-Diagnostics” or the “Company”) (NASDAQ:CODX) of the August 17, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you invested in Co-Diagnostics stock or options between February 25, 2020 and May 15, 2020 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org.
The lawsuit has been filed in the U.S. District Court for the District of Utah on behalf of all those who purchased Co-Diagnostics securities between February 25, 2020 and May 15, 2020 (the “Class Period”). The case, Gelt Trading v. Co-Diagnostics et al., No. 2:20-cv-00368 was filed on June 15, 2020, and has been assigned to Judge Cecilia M. Romero.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements about the accuracy of the Company’s Covid-19 tests.
On May 14, 2020, public reports casting doubt of the Company’s claims of Covid-19 100% test accuracy began to emerge.
In response to this news, the Company’s stock price fell from $22.13 per share on May 14, 2020 to $17.07 per share on May 15, 2020: a $5.06 or 22.84% drop.
Co-Diagnostics, Inc. (CODX)
* The submission of this form does not create an attorney-client relationship.
Filed on 06/15/2020
Lead Plaintiff Deadline 08/17/2020
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Richard W. Gonnello email@example.com Phone (212) 983-9330 Fax (212) 983-9331